Cost-effectiveness finding of KRAS testing for corresponding targeted therapies.</p
<p>Results of the base-case cost-effectiveness analysis and the probabilistic sensitivity analysis.<...
<p>ICER of cetuximab+FOLFOX <i>vs</i> bevacizumab+FOLFOX is lower than that of cetuximab+FOLFOX <i>v...
<p>Results of sensitivity analyses which altered cost-effective intervention.</p
Cost-effectiveness finding of RAS testing for corresponding targeted therapies.</p
<p>Results of the cost effectiveness analysis according to incremental cost effectiveness ratio (ICE...
<p>Cost-effectiveness analysis results for complete case and sensitivity analyses.</p
Sensitivity analysis results evaluating cost-effectiveness of Histoplasma antigen screening with tre...
Results of the main cost-effectiveness analysis of three different DAA treatment scenarios.</p
CGLAS: Results of cost-effectiveness analysis, treatment based on assignment and compliance.</p
<p>Results of base case cost-effectiveness analysis of test strategies for diagnosis of MD.</p
<p>One-way sensitivity analyses of cost-effectiveness for different anemia treatment targets.</p
Cost-effectiveness plane in incremental number of treatment success and incremental cost.</p
<p>Cost-effectiveness plane presenting all non-dominated and selected dominated screening protocols ...
Sensitivity analysis results evaluating cost-effectiveness of Histoplasma antigen prevalence of 15%....
Sensitivity analysis results evaluating cost-effectiveness of Histoplasma antigen prevalence of 5%.<...
<p>Results of the base-case cost-effectiveness analysis and the probabilistic sensitivity analysis.<...
<p>ICER of cetuximab+FOLFOX <i>vs</i> bevacizumab+FOLFOX is lower than that of cetuximab+FOLFOX <i>v...
<p>Results of sensitivity analyses which altered cost-effective intervention.</p
Cost-effectiveness finding of RAS testing for corresponding targeted therapies.</p
<p>Results of the cost effectiveness analysis according to incremental cost effectiveness ratio (ICE...
<p>Cost-effectiveness analysis results for complete case and sensitivity analyses.</p
Sensitivity analysis results evaluating cost-effectiveness of Histoplasma antigen screening with tre...
Results of the main cost-effectiveness analysis of three different DAA treatment scenarios.</p
CGLAS: Results of cost-effectiveness analysis, treatment based on assignment and compliance.</p
<p>Results of base case cost-effectiveness analysis of test strategies for diagnosis of MD.</p
<p>One-way sensitivity analyses of cost-effectiveness for different anemia treatment targets.</p
Cost-effectiveness plane in incremental number of treatment success and incremental cost.</p
<p>Cost-effectiveness plane presenting all non-dominated and selected dominated screening protocols ...
Sensitivity analysis results evaluating cost-effectiveness of Histoplasma antigen prevalence of 15%....
Sensitivity analysis results evaluating cost-effectiveness of Histoplasma antigen prevalence of 5%.<...
<p>Results of the base-case cost-effectiveness analysis and the probabilistic sensitivity analysis.<...
<p>ICER of cetuximab+FOLFOX <i>vs</i> bevacizumab+FOLFOX is lower than that of cetuximab+FOLFOX <i>v...
<p>Results of sensitivity analyses which altered cost-effective intervention.</p
DOI
Add to ORKG